Beijing Huixin Medical Valley Biotechnology
Stem cell therapies for neurological diseases
About Beijing Huixin Medical Valley Biotechnology
Beijing Huixin Medical Valley Biotechnology, also known as Wiseheart Medval, is a biotechnology company founded in 2021 and based in Beijing, China. The firm specializes in developing stem cell therapies and drugs for neurological diseases, with a particular focus on Parkinson's disease.
The company's core technology involves using somatic cell reprogramming and a non-integrated system to directly induce neural stem cells (iNSCs) from a patient's own peripheral blood mononuclear cells or fibroblasts. These iNSCs are then differentiated into specific nerve cells. A key product in its pipeline is a dopaminergic neural precursor cell (iNSC-DAP) injection, which is developed from these induced neural stem cells for the treatment of Parkinson's.
Operating as a privately held, venture capital-backed entity, Wiseheart Medval has secured funding from investors including Beijing Innovation Industry Investment, Jiuzhi Capital, and Green Pine Capital Partners. In January 2026, the company reportedly raised $14.0 million in a Series A funding round. The company serves patients with neurological disorders and operates within the competitive biotechnology and cell therapy markets.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Neurology, Stem Cells, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2026 | $28M | $110M | BCT Capital · Beijing Fuzhi Investment Management | ↗ |
| SEED✓Equity / VC | Feb 2024 | $2.8M | $11M | Jiuzhi Capital · Beijing Innovation Industry Investment | ↗ |
Growth signals
Latest recorded traffic for Beijing Huixin Medical Valley Biotechnology is 500 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Huixin Medical Valley Biotechnology in its local ecosystem
The Beijing Huixin Medical Valley Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Green Pine Capital
Jiuzhi Capital- BIBeijing Innovation Industry Investment
Series A2 investors entered at this stage
BCT Capital- BMBeijing Fuzhi Investment Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Huixin Medical Valley Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Huixin Medical Valley Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








